Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW DAVIS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1629238860
CMS profile
210014
Location
MIDDLETOWN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$134,586.20

175 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW DAVIS

NPI 1629238860 · CMS profile ID 210014

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

MIDDLETOWN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629238860?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW DAVIS, NPI 1629238860, CMS profile ID 210014. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629238860?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MATTHEW DAVIS, NPI 1629238860, CMS profile ID 210014. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629238860?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MATTHEW DAVIS, NPI 1629238860, CMS profile ID 210014, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1629238860?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

175 matching records · $134,586.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 175 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 175.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $203.1706/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400031 CMS
UCB, Inc. $16.4806/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021414885 CMS
PFIZER INC. $4.4206/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049386197 CMS
JAZZ PHARMACEUTICALS INC. $6,030.0006/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058403357 CMS
Axsome Therapeutics, Inc. $68.7506/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056187817 CMS
JAZZ PHARMACEUTICALS INC. $135.0006/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058395459 CMS
JAZZ PHARMACEUTICALS INC. $24.2206/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058399221 CMS
JAZZ PHARMACEUTICALS INC. $302.0406/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404249 CMS
ZOLL Respicardia, Inc. $17.7106/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045728715 CMS
JAZZ PHARMACEUTICALS INC. $44.4806/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404195 CMS
JAZZ PHARMACEUTICALS INC. $573.0006/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404589 CMS
UCB, Inc. $14.3506/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021414877 CMS
Neurocrine Biosciences, Inc. $15.0005/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052331047 CMS
JAZZ PHARMACEUTICALS INC. $238.7105/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404101 CMS
JAZZ PHARMACEUTICALS INC. $677.8005/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404857 CMS
Harmony Biosciences LLC $15.7605/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013663329 CMS
Harmony Biosciences LLC $2,492.0005/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013593529 CMS
Harmony Biosciences LLC $117.6605/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013593667 CMS
AbbVie Inc. $10.0205/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996606819 CMS
JAZZ PHARMACEUTICALS INC. $230.5605/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401581 CMS
JAZZ PHARMACEUTICALS INC. $4,690.0005/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401967 CMS
JAZZ PHARMACEUTICALS INC. $65.0005/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404357 CMS
JAZZ PHARMACEUTICALS INC. $547.8005/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400053 CMS
JAZZ PHARMACEUTICALS INC. $117.8705/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058402003 CMS
JAZZ PHARMACEUTICALS INC. $6,030.0005/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404699 CMS
UCB, Inc. $18.1305/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021414899 CMS
Axsome Therapeutics, Inc. $15.1105/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056187747 CMS
JAZZ PHARMACEUTICALS INC. $1,005.0005/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401973 CMS
JAZZ PHARMACEUTICALS INC. $757.8104/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404197 CMS
JAZZ PHARMACEUTICALS INC. $226.8604/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058403761 CMS
Biogen, Inc. $25.9404/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012207959 CMS
JAZZ PHARMACEUTICALS INC. $4,690.0004/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401537 CMS
PFIZER INC. $5.5504/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049184357 CMS
JAZZ PHARMACEUTICALS INC. $16.5604/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058394575 CMS
JAZZ PHARMACEUTICALS INC. $228.8504/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401545 CMS
JAZZ PHARMACEUTICALS INC. $122.0604/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058401485 CMS
AbbVie Inc. $28.5404/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996606815 CMS
JAZZ PHARMACEUTICALS INC. $298.8804/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404825 CMS
JAZZ PHARMACEUTICALS INC. $138.8604/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404275 CMS
JAZZ PHARMACEUTICALS INC. $4,690.0004/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404393 CMS
JAZZ PHARMACEUTICALS INC. $121.8303/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404475 CMS
JAZZ PHARMACEUTICALS INC. $6,030.0003/29/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404259 CMS
Axsome Therapeutics, Inc. $1,200.0003/28/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056187773 CMS
JAZZ PHARMACEUTICALS INC. $247.8003/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058404583 CMS
JAZZ PHARMACEUTICALS INC. $118.7503/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058403563 CMS
JAZZ PHARMACEUTICALS INC. $4,690.0003/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058405029 CMS
Harmony Biosciences LLC $13.4903/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013663321 CMS
JAZZ PHARMACEUTICALS INC. $16.8503/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058394553 CMS
IDORSIA PHARMACEUTICALS US INC $1,470.0003/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034506427 CMS
JAZZ PHARMACEUTICALS INC. $112.1503/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058405025 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,200.24 79
PY2020 $563.92 30
PY2021 $9,843.44 50
PY2022 $107,728.71 183
PY2023 $134,586.20 175
PY2024 $146,063.25 248
PY2025 $166,952.99 237

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $133,030.90 90
PY2024 Principal investigator $38,924.51 25
PY2023 Principal investigator $28,136.21 15
PY2022 Principal investigator $17,649.75 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $70.00 12/23/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622559
Principal investigator 1 Alkermes, Inc. $382.00 11/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613075
Principal investigator 1 Alkermes, Inc. $832.00 11/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614591
Principal investigator 1 Alkermes, Inc. $832.00 11/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617143
Principal investigator 1 Alkermes, Inc. $382.00 11/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619199
Principal investigator 1 Alkermes, Inc. $2,739.00 11/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622711
Principal investigator 1 Alkermes, Inc. $382.00 11/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625179
Principal investigator 1 Alkermes, Inc. $3,364.00 11/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626470
Principal investigator 1 Alkermes, Inc. $2,500.00 10/10/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615215
Principal investigator 1 Alkermes, Inc. $8,000.00 10/10/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615615
Principal investigator 1 Alkermes, Inc. $6,987.00 10/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614148
Principal investigator 1 Alkermes, Inc. $2,793.00 10/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618719
Principal investigator 1 Alkermes, Inc. $8,527.00 10/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621626
Principal investigator 1 Alkermes, Inc. $6,710.00 10/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624740
Principal investigator 1 Alkermes, Inc. $2,739.00 10/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626058
Principal investigator 1 Alkermes, Inc. $2,922.00 09/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613159
Principal investigator 1 Alkermes, Inc. $7,699.00 09/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617237
Principal investigator 1 Alkermes, Inc. $3,008.00 09/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618103
Principal investigator 1 Alkermes, Inc. $5,310.00 09/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621716
Principal investigator 1 Alkermes, Inc. $4,586.00 09/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623300
Principal investigator 1 Alkermes, Inc. $2,922.00 09/08/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624614
Principal investigator 1 Alkermes, Inc. $4.20 09/04/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620029
Principal investigator 1 Alkermes, Inc. $21.40 09/04/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623522
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616393
Principal investigator 1 Alkermes, Inc. $75.20 09/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619045
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619791
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620027
Principal investigator 1 Alkermes, Inc. $56.40 09/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624852
Principal investigator 1 Alkermes, Inc. $70.00 08/14/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615453
Principal investigator 1 Alkermes, Inc. $77.10 08/05/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616787
Principal investigator 1 Alkermes, Inc. $1.74 08/05/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622169
Principal investigator 1 Alkermes, Inc. $74.24 08/05/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623042
Principal investigator 1 Alkermes, Inc. $72.80 08/05/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624616
Principal investigator 1 Novo Nordisk AS $1,103.83 07/16/2025 Non-covered Recipient Entity
PATIENT FIRST MD ADVANCED CENTER FOR NEURODIAGNOSTICS
NN6535-4725 No dispute reported 06/30/2026 1213824010
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613752
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613816
Principal investigator 1 Alkermes, Inc. $72.80 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614076
Principal investigator 1 Alkermes, Inc. $54.60 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614078
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615279
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615991
Principal investigator 1 Alkermes, Inc. $2.14 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617901
Principal investigator 1 Alkermes, Inc. $21.56 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618085
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618633
Principal investigator 1 Alkermes, Inc. $3.85 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619317
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619587
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620926
Principal investigator 1 Alkermes, Inc. $25.68 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621162
Principal investigator 1 Alkermes, Inc. $1.05 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621342
Principal investigator 1 Alkermes, Inc. $19.60 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621500
Principal investigator 1 Alkermes, Inc. $54.60 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621750
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622219
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623288
Principal investigator 1 Alkermes, Inc. $2.10 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623334
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623780
Principal investigator 1 Alkermes, Inc. $77.10 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624648
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625261
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626110
Principal investigator 1 Alkermes, Inc. $115.65 06/18/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626598
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613545
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619267
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619757
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622783
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623512
Principal investigator 1 Alkermes, Inc. $135.00 06/06/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626550
Principal investigator 1 Novo Nordisk AS $1,103.83 05/21/2025 Non-covered Recipient Entity
PATIENT FIRST MD ADVANCED CENTER FOR NEURODIAGNOSTICS
NN6535-4725 No dispute reported 06/30/2026 1213794299
Principal investigator 1 Alkermes, Inc. $1,045.00 04/22/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616089
Principal investigator 1 Alkermes, Inc. $1,045.00 04/22/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617587
Principal investigator 1 Novo Nordisk AS $3,075.16 04/21/2025 Non-covered Recipient Entity
PATIENT FIRST MD ADVANCED CENTER FOR NEURODIAGNOSTICS
NN6535-4725 No dispute reported 06/30/2026 1213779178
Principal investigator 1 Alkermes, Inc. $1,196.53 04/09/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615089
Principal investigator 1 Alkermes, Inc. $259.54 04/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614503
Principal investigator 1 Alkermes, Inc. $119.36 04/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617481
Principal investigator 1 Alkermes, Inc. $113.34 04/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618169
Principal investigator 1 Alkermes, Inc. $56.85 04/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620730
Principal investigator 1 Alkermes, Inc. $82.08 04/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621991
Principal investigator 1 Alkermes, Inc. $77.64 04/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621993
Principal investigator 1 Alkermes, Inc. $52.48 04/03/2025 Non-covered Recipient Entity
PATIENT FIRST MD
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624232
Principal investigator 1 Novo Nordisk AS $3,318.16 03/28/2025 Non-covered Recipient Entity
PATIENT FIRST MD ADVANCED CENTER FOR NEURODIAGNOSTICS
NN6535-4725 No dispute reported 06/30/2026 1213757910
Principal investigator 1 Alkermes, Inc. $218.45 02/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613087
Principal investigator 1 Alkermes, Inc. $22.50 02/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616727
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616953
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621660
Principal investigator 1 Alkermes, Inc. $16.00 02/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621903
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624344
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624965
Principal investigator 1 Alkermes, Inc. $70.40 02/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625441
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626492
Principal investigator 1 Novo Nordisk AS $877.23 01/31/2025 Non-covered Recipient Entity
PATIENT FIRST MD ADVANCED CENTER FOR NEURODIAGNOSTICS
NN6535-4725 No dispute reported 06/30/2026 1213821071
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627064
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
PATIENT FIRST MD
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627138
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
PATIENT FIRST MD
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627214